• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Monoclonal antibodies in neuroinflammatory diseases
【24h】

Monoclonal antibodies in neuroinflammatory diseases

机译：神经炎性疾病的单克隆抗体

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Monoclonal antibodies (mAbs) represent an emerging and rapidly growing field of therapy in neuroinflammatory diseases. Adhesion molecule blockade by natalizumab represents the first approved mAb therapy in neurology, approved for therapy of highly active multiple sclerosis (MS). Removal of immune cells by anti-CD52 mAb alemtuzumab or anti-CD20 mAb rituximab are other prime examples with existing positive Phase II and Phase III trials. MS clearly represents the neuroinflammatory disease entity with the largest body of evidence. However, some of these approaches are currently investigated or translated for use in other, rare neuroinflammatory diseases, such as neuromyelitis optica (NMO), inflammatory neuropathies and (neuro)-muscular disorders. Areas covered: This review will highlight the most relevant therapeutic approaches involving mAbs in the field of neuroinflammatory diseases as published in peer-reviewed journals and presented on international meetings. Expert opinion: There is continuously growing evidence on the therapeutic relevance of mAbs in neuroinflammatory disorders. In MS meanwhile several studies have provided evidence for efficacy: In addition to natalizumab, approved in 2006, several other candidates are under development, the most eminent examples with the most advanced study programs being anti-CD52 alemtuzumab, anti-CD20 principles and anti-CD25 daclizumab. Other intriguing candidates are anti-IL-17 strategies, and interference with the complement pathway, partly also developed for other neuroinflammatory disorders.
机译：简介：单克隆抗体（mAbs）代表了神经炎性疾病中新兴的且迅速发展的治疗领域。那他珠单抗对粘附分子的阻断代表了神经病学中第一个批准的单克隆抗体疗法，该疗法被批准用于治疗高度活跃的多发性硬化症（MS）。抗CD52单克隆抗体alemtuzumab或抗CD20单克隆抗体利妥昔单抗去除免疫细胞是现有II期和III期阳性试验的其他主要实例。 MS清楚地代表了具有最多证据的神经炎性疾病实体。但是，目前已研究或翻译了其中一些方法，以用于其他罕见的神经炎性疾病，例如视神经脊髓炎（NMO），炎性神经病和（神经）肌肉疾病。涵盖领域：本综述将重点介绍神经炎性疾病领域涉及单克隆抗体的最相关治疗方法，该方法发表在同行评审期刊上并在国际会议上发表。专家意见：单克隆抗体在神经炎性疾病中的治疗意义一直在不断增长。与此同时，在MS中有几项研究提供了疗效证据：除了2006年批准的那他珠单抗外，还有其他几项候选药物正在研发中，其中最著名的例子是抗CD52阿仑单抗，抗CD20原理和抗CD25达珠单抗。其他有趣的候选药物是抗IL-17策略，并且对补体途径的干扰也部分针对其他神经炎性疾病而发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号